NCT04201574View on ClinicalTrials.gov

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

September 15, 2020

Study Completion Date

September 15, 2020

Conditions
Dry Eye Disease
Interventions
DRUG

ALY688 0.1%

ALY688 0.1% Ophthalmic Solution

DRUG

ALY688 0.4%

ALY688 0.4% Ophthalmic Solution

DRUG

Vehicle

Vehicle Ophthalmic Solution

Trial Locations (1)

98006

Allysta Pharmaceuticals, Bellevue

Sponsors
All Listed Sponsors
lead

Allysta Pharmaceutical

INDUSTRY

NCT04201574 - Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease | Biotech Hunter | Biotech Hunter